The use of PRMT5 inhibitors along with the chemotherapeutic agent gemcitabine has been shown to have a synergistic effect in tumor growth inhibition in PDAC cells through enhanced DNA damage [68]. The gene discussed is PRMT5; the disease is neoplasm.